WO2002094284A1 - Method of treating dry eye disorders - Google Patents

Method of treating dry eye disorders Download PDF

Info

Publication number
WO2002094284A1
WO2002094284A1 PCT/US2002/015784 US0215784W WO02094284A1 WO 2002094284 A1 WO2002094284 A1 WO 2002094284A1 US 0215784 W US0215784 W US 0215784W WO 02094284 A1 WO02094284 A1 WO 02094284A1
Authority
WO
WIPO (PCT)
Prior art keywords
dry eye
eye
compositions
stigmastan
pentahydroxy
Prior art date
Application number
PCT/US2002/015784
Other languages
French (fr)
Inventor
John M. Yanni
Daniel A. Gamache
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Priority to CA002447918A priority Critical patent/CA2447918A1/en
Priority to JP2002591001A priority patent/JP2004531560A/en
Priority to EP02746411A priority patent/EP1392322A1/en
Priority to BR0209882-2A priority patent/BR0209882A/en
Publication of WO2002094284A1 publication Critical patent/WO2002094284A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • the present invention is directed to the treatment of dry eye disorders.
  • the present invention is directed toward the use of 22,29-epoxy- 3,4,6,7,29-pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)-stigmastan-15-one in the treatment of dry eye and other disorders requiring the wetting of the eye in mammals.
  • Dry eye also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease and cicatricial pemphigoid manifest dry eye complications.
  • Practitioners have taken several approaches to the treatment of dry eye.
  • One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day.
  • Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
  • Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils.
  • Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye, Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley, Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality, Archives of Ophthalmology, volume 116(7), pages 849-52 (1998).
  • phospholipid compositions for the treatment of dry eye are disclosed in U.S. Patent Nos. 4,131 ,651 (Shah et al.), 4,370,325 (Packman), 4,409,205 (Shively), 4,744,980 and 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371 ,108 (Korb et al.) and 5,578,586 (Glonek et al.).
  • U.S. Patent No. 5,174,988 discloses phospholipid drug delivery systems involving phospholipids, propellants and an active substance.
  • U.S. Patent No. 4,818,537 discloses the use of a lubricating, liposome-based composition
  • U.S. Patent No. 5,800,807 discloses compositions containing glycerin and propylene glycol for treating dry eye.
  • U.S. Patent No. 5,041 ,434 discloses the use of sex steroids, such as conjugated estrogens, to treat dry eye conditions in post-menopausal women
  • U.S. Patent No. 5,290,572 discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production
  • U.S. Patent No. 4,966,773 discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
  • Corticosteroids such as prednisolone, dexamethasone, fluoromethalone, hydrocortisone, loteprednol, triamcinolone, etc.
  • Steroid-related complications including increased intraocular pressure and cataract formation have been observed in dry eye patients treated with corticosteroids after several months of therapy. See Marsh, et al., Ophthalmology, 106(4): 811-816 (1999). Marsh, et al.
  • U.S. Patent No. 6,046,185 discloses 6,7-oxygenated steroids, including 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)- stigmastan-15-one, for use in the treatment of asthma, allergy, inflammation including arthritis and thrombosis. Kuriakose, et al., J.
  • the present invention is directed to methods for the treatment of dry eye and other disorders requiring the wetting of the eye, including symptoms of dry eye associated with refractive surgery such as LASIK surgery.
  • 22,29-epoxy-3,4,6,7,29- pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)-stigmastan-15-one is administered to a patient suffering from dry eye or other disorders requiring wetting of the eye.
  • the methods of the present invention have reduced risk of steroid- related complications compared to methods involving compounds that have a glucocorticoid's mechanism of action.
  • the 22,29-epoxy-3,4,6,7,29- pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)-stigmastan-15-one is preferably administered topically to the eye.
  • 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)- stigmastan-15-one is a known compound and can be synthesized by methods disclosed in U.S. Patent No. 6,046,185, the entire contents of which are hereby incorporated by reference in the present specification. This compound is also known by the code name IPL576.092.
  • compositions comprising 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)- stigmastan-15-one and a pharmaceutically acceptable carrier for topical ophthalmic administration or implantation into the conjunctival sac or anterior chamber of the eye is administered to a mammal in need thereof.
  • the compositions are formulated in accordance with methods known in the art for the particular route of administration desired.
  • compositions administered according to the present invention comprise a pharmaceutically effective amount of 22,29-epoxy-3,4,6,7,29- pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)-stigmastan-15-one.
  • a "pharmaceutically effective amount” is one which is sufficient to reduce or eliminate signs or symptoms of dry eye or other disorders requiring the wetting of the eye.
  • compositions administered according to the present invention may also include various other ingredients, including but not limited to surfactants, tonicity agents, buffers, preservatives, co-solvents and viscosity building agents.
  • tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions.
  • sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose and/or mannitol may be added to the composition to approximate physiological tonicity.
  • Such an amount of tonicity agent will vary, depending on the particular agent to be added.
  • the compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150 - 450 mOsm, preferably 250 - 350 mOsm).
  • An appropriate buffer system e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid
  • the particular concentration will vary, depending on the agent employed.
  • the buffer will be chosen to maintain a target pH within the range of pH 6-7.5.
  • compositions formulated for the treatment of dry eye-type diseases and disorders may also comprise aqueous carriers designed to provide immediate, short-term relief of dry eye-type conditions.
  • aqueous carriers designed to provide immediate, short-term relief of dry eye-type conditions.
  • Such carriers can be formulated as a phospholipid carrier or an artificial tears carrier, or mixtures of both.
  • phospholipid carrier and “artificial tears carrier” refer to aqueous compositions which: (i) comprise one or more phospholipids (in the case of phospholipid carriers) or other compounds, which lubricate, "wet,” approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration; (ii) are safe; and (iii) provide the appropriate delivery vehicle for the topical administration of an effective amount of 22,29- epoxy-3,4,6,7,29-pentahydroxy-,(3 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ ,7 ⁇ ,14 ⁇ ,22S)-stigmastan-15- one.
  • artificial tears compositions useful as artificial tears carriers include, but are not limited to, commercial products, such as Tears Naturale®, Tears Naturale II®, Tears Naturale Free®, and Bion Tears® (Alcon Laboratories, Inc., Fort Worth, Texas).
  • phospholipid carrier formulations include those disclosed in U.S. Patent Nos.
  • Such compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose ("HPMC"), carboxy methylcellulose sodium, hydroxy propylcellulose (“HPC”), dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941 , carbomer 940, carbomer 974P.
  • monomeric polyols such as, glycerol, propylene glycol, ethylene glycol
  • polymeric polyols such as, polyethylene glycol, hydroxypropylmethyl cellulose ("HPMC”), carboxy methylcellulose sodium, hydroxy propylcellulose (“HPC”), de
  • viscosity enhancing agents include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; vinyl polymers; and acrylic acid polymers.
  • the phospholipid carrier or artificial tears carrier compositions will exhibit a viscosity of 1 to 400 centipoises ("cps").
  • Topical ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquatemium-1 , or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.
  • compositions of the present invention are intended for administration to a human patient suffering from dry eye or symptoms of dry eye.
  • such compositions will be administered topically.
  • the doses used for the above described purposes will vary, but will be in an effective amount to eliminate or improve dry eye conditions.
  • 1-2 drops of such compositions will be administered from once to many times per day.
  • a representative eye drop formulation is provided in Example 1 below.
  • Example 1 can be prepared using a slight modification of the method disclosed in U.S. Patent No. 6,071 ,904. Briefly, a concentrated slurry of 22,29-epoxy-3,4,6,7,29-pentahydroxy-
  • aqueous slurry is a mixture containing 3-mm zirconium beads, the total required amount of drug and polysorbate 80 and approximately one-half of the required amounts of benzalkonium chloride and disodium edetate. After autoclaving, the drug slurry is ball milled for approximately 18 hrs at approximately 50-55 rpm.
  • the milling beads are removed from the milled slurry by filtration as the milled slurry is aseptically added to an autoclaved aqueous vehicle (pH adjusted to 7.2 with NaOH/HCI) containing the required amounts of sodium chloride and carbomer 974P and the remaining amounts of benzalkonium chloride, and disodium edetate.
  • the sterile product is then adjusted to the final batch weight with sterile purified water and thoroughly mixed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one is useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

Description

Method of Treating Dry Eye Disorders
The present invention is directed to the treatment of dry eye disorders. In particular, the present invention is directed toward the use of 22,29-epoxy- 3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one in the treatment of dry eye and other disorders requiring the wetting of the eye in mammals.
Background of the Invention
Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease and cicatricial pemphigoid manifest dry eye complications.
Although it appears that dry eye may result from a number of unrelated pathogenic causes, all presentations of the complication share a common effect, that is the breakdown of the pre-ocular tear film, which results in dehydration of the exposed outer surface and many of the symptoms outlined above (Lemp, Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes, The CLAO Journal, volume 21 , number 4, pages 221-231 (1995)).
Practitioners have taken several approaches to the treatment of dry eye. One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day. Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils. Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye, Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley, Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality, Archives of Ophthalmology, volume 116(7), pages 849-52 (1998). Examples of phospholipid compositions for the treatment of dry eye are disclosed in U.S. Patent Nos. 4,131 ,651 (Shah et al.), 4,370,325 (Packman), 4,409,205 (Shively), 4,744,980 and 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371 ,108 (Korb et al.) and 5,578,586 (Glonek et al.). U.S. Patent No. 5,174,988 (Mautone et al.) discloses phospholipid drug delivery systems involving phospholipids, propellants and an active substance.
Another approach involves the provision of lubricating substances in lieu of artificial tears. For example, U.S. Patent No. 4,818,537 (Guo) discloses the use of a lubricating, liposome-based composition, and U.S. Patent No. 5,800,807 (Hu et al.) discloses compositions containing glycerin and propylene glycol for treating dry eye.
Although these approaches have met with some success, problems in the treatment of dry eye nevertheless remain. The use of tear substitutes, while temporarily effective, generally requires repeated application over the course of a patient's waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day. Such an undertaking is not only cumbersome and time consuming, but is also potentially very expensive. Transient symptoms of dry eye associated with refractive surgery have been reported to last in some cases from six weeks to six months or more following surgery.
Aside from efforts directed primarily to the alleviation of symptoms associated with dry eye, methods and compositions directed to treatment of the dry eye condition have also been pursued. For example, U.S. Patent No. 5,041 ,434 (Lubkin) discloses the use of sex steroids, such as conjugated estrogens, to treat dry eye conditions in post-menopausal women; U.S. Patent No. 5,290,572 (MacKeen) discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production; and U.S. Patent No. 4,966,773 (Gressel et al.) discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
Some recent literature reports suggest that patients suffering from dry eye syndrome disproportionately exhibit the hallmarks of excessive inflammation in relevant ocular tissues, such as the lacrimal and meibomian glands. The use of various compounds to treat dry eye patients, such as steroids [e.g. U.S. Patent No. 5,958,912; Marsh, et al., Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome, Ophthalmology, 106(4): 811-816 (1999); Pflugfelder, et. al. U.S. Patent No. 6,153,607], cytokine release inhibitors (Yanni, J.M.; et. al. WO 0003705 A1), cyclosporine A [Tauber, J. Adv. Exp. Med. Biol. 1998, 438 (Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2), 969], and 15-HETE (Yanni et. al., US Patent No. 5,696,166), has been disclosed.
Corticosteroids, such as prednisolone, dexamethasone, fluoromethalone, hydrocortisone, loteprednol, triamcinolone, etc., cannot be used for prolonged therapy in dry eye patients without causing side effects. Steroid-related complications including increased intraocular pressure and cataract formation have been observed in dry eye patients treated with corticosteroids after several months of therapy. See Marsh, et al., Ophthalmology, 106(4): 811-816 (1999). Marsh, et al. conclude: "Because of the chronic nature of [dry eye] disease and the likelihood of patients developing steroid-related complications with their long-term use, topical nonpreserved methylprednisolone therapy appears to be most appropriate for short-term 'pulse' treatment of exacerbations of keratoconjunctivits sicca." Id. at 811.
U.S. Patent No. 6,046,185 discloses 6,7-oxygenated steroids, including 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)- stigmastan-15-one, for use in the treatment of asthma, allergy, inflammation including arthritis and thrombosis. Kuriakose, et al., J. Allergy Clin Immunol, 107(2), S97, Abstract #326, discloses that 22,29-epoxy-3,4,6,7,29- pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one has demonstrated significant anti-inflammatory properties, but that it has a mechanism of action distinct from that of glucocorticoids such as dexamethasone. Kuriakose, et al. conclude that despite its steroidal backbone, it is "distinctly different from a classic glucocorticoid." Neither the '185 patent nor Kuriakose, et al. mentions the use of any compounds for the topical treatment of dry eye.
Summary of the Invention
The present invention is directed to methods for the treatment of dry eye and other disorders requiring the wetting of the eye, including symptoms of dry eye associated with refractive surgery such as LASIK surgery. According to the methods of the present invention, 22,29-epoxy-3,4,6,7,29- pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one is administered to a patient suffering from dry eye or other disorders requiring wetting of the eye. The methods of the present invention have reduced risk of steroid- related complications compared to methods involving compounds that have a glucocorticoid's mechanism of action. The 22,29-epoxy-3,4,6,7,29- pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one is preferably administered topically to the eye.
Detailed Description of the Invention
22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)- stigmastan-15-one is a known compound and can be synthesized by methods disclosed in U.S. Patent No. 6,046,185, the entire contents of which are hereby incorporated by reference in the present specification. This compound is also known by the code name IPL576.092.
According to the methods of the present invention, a composition comprising 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)- stigmastan-15-one and a pharmaceutically acceptable carrier for topical ophthalmic administration or implantation into the conjunctival sac or anterior chamber of the eye is administered to a mammal in need thereof. The compositions are formulated in accordance with methods known in the art for the particular route of administration desired.
The compositions administered according to the present invention comprise a pharmaceutically effective amount of 22,29-epoxy-3,4,6,7,29- pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one. As used herein, a "pharmaceutically effective amount" is one which is sufficient to reduce or eliminate signs or symptoms of dry eye or other disorders requiring the wetting of the eye. Generally, for compositions intended to be administered topically to the eye in the form of eye drops or eye ointments, the amount of 22,29-epoxy-3,4,6,7,29-pentahydroxy-
,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one will be about 0.001 to 5.0% (w/v). For preferred topically administrable ophthalmic compositions, the amount of 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)- stigmastan-15-one will be about 0.001 to 1.0% (w/v).
The compositions administered according to the present invention may also include various other ingredients, including but not limited to surfactants, tonicity agents, buffers, preservatives, co-solvents and viscosity building agents.
Various tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose and/or mannitol may be added to the composition to approximate physiological tonicity. Such an amount of tonicity agent will vary, depending on the particular agent to be added. In general, however, the compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150 - 450 mOsm, preferably 250 - 350 mOsm).
An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid) may be added to the compositions to prevent pH drift under storage conditions. The particular concentration will vary, depending on the agent employed. Preferably, however, the buffer will be chosen to maintain a target pH within the range of pH 6-7.5.
Compositions formulated for the treatment of dry eye-type diseases and disorders may also comprise aqueous carriers designed to provide immediate, short-term relief of dry eye-type conditions. Such carriers can be formulated as a phospholipid carrier or an artificial tears carrier, or mixtures of both. As used herein, "phospholipid carrier" and "artificial tears carrier" refer to aqueous compositions which: (i) comprise one or more phospholipids (in the case of phospholipid carriers) or other compounds, which lubricate, "wet," approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration; (ii) are safe; and (iii) provide the appropriate delivery vehicle for the topical administration of an effective amount of 22,29- epoxy-3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15- one. Examples or artificial tears compositions useful as artificial tears carriers include, but are not limited to, commercial products, such as Tears Naturale®, Tears Naturale II®, Tears Naturale Free®, and Bion Tears® (Alcon Laboratories, Inc., Fort Worth, Texas). Examples of phospholipid carrier formulations include those disclosed in U.S. Patent Nos. 4,804,539 (Guo et al.), 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371 ,108 (Korb et al.), 5,578,586 (Glonek et al.); the foregoing patents are incorporated herein by reference to the extent they disclose phospholipid compositions useful as phospholipid carriers of the present invention.
Other compounds designed to lubricate, "wet," approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration the eye are known in the art. Such compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose ("HPMC"), carboxy methylcellulose sodium, hydroxy propylcellulose ("HPC"), dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941 , carbomer 940, carbomer 974P. Other compounds may also be added to the ophthalmic compositions of the present invention to increase the viscosity of the carrier. Examples of viscosity enhancing agents include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; vinyl polymers; and acrylic acid polymers. In general, the phospholipid carrier or artificial tears carrier compositions will exhibit a viscosity of 1 to 400 centipoises ("cps").
Topical ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquatemium-1 , or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.
The preferred compositions of the present invention are intended for administration to a human patient suffering from dry eye or symptoms of dry eye. Preferably, such compositions will be administered topically. In general, the doses used for the above described purposes will vary, but will be in an effective amount to eliminate or improve dry eye conditions. Generally, 1-2 drops of such compositions will be administered from once to many times per day.
A representative eye drop formulation is provided in Example 1 below.
Example 1
Figure imgf000010_0001
The composition of Example 1 can be prepared using a slight modification of the method disclosed in U.S. Patent No. 6,071 ,904. Briefly, a concentrated slurry of 22,29-epoxy-3,4,6,7,29-pentahydroxy-
,(3 ,4β,5α,6α,7β,14β,22S)-stigmastan-15-one in a milling bottle is autoclaved. The aqueous slurry is a mixture containing 3-mm zirconium beads, the total required amount of drug and polysorbate 80 and approximately one-half of the required amounts of benzalkonium chloride and disodium edetate. After autoclaving, the drug slurry is ball milled for approximately 18 hrs at approximately 50-55 rpm. After milling, the milling beads are removed from the milled slurry by filtration as the milled slurry is aseptically added to an autoclaved aqueous vehicle (pH adjusted to 7.2 with NaOH/HCI) containing the required amounts of sodium chloride and carbomer 974P and the remaining amounts of benzalkonium chloride, and disodium edetate. The sterile product is then adjusted to the final batch weight with sterile purified water and thoroughly mixed. This invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its special or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims

WHAT IS CLAIMED IS:
1. A method for the treatment of dry eye and other disorders requiring the wetting of the eye which comprises administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of 22,29-epoxy-3,4,6,7,29-pentahydroxy- s ,(3α,4β,5α,6α,7β,14β,22S)-stigmastan-15-one.
2. The method of Claim 1 wherein the pharmaceutically effective amount of 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)- stigmastan-15-one is 0.001 - 5.0% (w/v). 0
3. The method of Claim 2 wherein the pharmaceutically effective amount of 22,29-epoxy-3,
4,6,7,29-pentahydroxy-,(3α,4β,5α,6α,7β,14β,22S)- stigmastan-15-one is 0.001 - 1.0% (w/v).
s 4. The method of Claim 1 wherein the composition is topically administered to the eye.
5. The method of Claim 1 wherein the dry eye and other disorders requiring the wetting of the eye is symptoms of dry eye associated with 0 refractive surgery.
PCT/US2002/015784 2001-05-21 2002-05-17 Method of treating dry eye disorders WO2002094284A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002447918A CA2447918A1 (en) 2001-05-21 2002-05-17 Method of treating dry eye disorders
JP2002591001A JP2004531560A (en) 2001-05-21 2002-05-17 How to treat dry eye disorders
EP02746411A EP1392322A1 (en) 2001-05-21 2002-05-17 Method of treating dry eye disorders
BR0209882-2A BR0209882A (en) 2001-05-21 2002-05-17 Method for treating dry eye disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29250001P 2001-05-21 2001-05-21
US60/292,500 2001-05-21

Publications (1)

Publication Number Publication Date
WO2002094284A1 true WO2002094284A1 (en) 2002-11-28

Family

ID=23124938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/015784 WO2002094284A1 (en) 2001-05-21 2002-05-17 Method of treating dry eye disorders

Country Status (10)

Country Link
US (1) US20030008853A1 (en)
EP (1) EP1392322A1 (en)
JP (1) JP2004531560A (en)
CN (1) CN1239161C (en)
BR (1) BR0209882A (en)
CA (1) CA2447918A1 (en)
MX (1) MXPA03010633A (en)
PL (1) PL367097A1 (en)
WO (1) WO2002094284A1 (en)
ZA (1) ZA200308770B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330762T3 (en) 2004-03-25 2009-12-15 BAUSCH & LOMB INCORPORATED USE OF LOTEPREDNOL ETABONATE FOR DRY EYE TREATMENT.
PL2018426T3 (en) * 2006-05-19 2013-10-31 Alcon Res Ltd Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527851A (en) * 1894-10-23 Process of reducing aluminium
US3991759A (en) * 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4744980A (en) * 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) * 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) * 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
EP0459148B1 (en) * 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Dry eye treatment composition
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE141502T1 (en) * 1991-01-15 1996-09-15 Alcon Lab Inc USE OF CARRAGEENAN IN TOPICAL OPHTHALMOLOGICAL COMPOSITIONS
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
JPH07508716A (en) * 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド Ocular androgen therapy in Sjogren's syndrome
US5506221A (en) * 1992-12-24 1996-04-09 University Of British Columbia Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agents
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
WO1998053806A1 (en) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
CA2444696A1 (en) * 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
US20040076691A1 (en) * 2002-01-16 2004-04-22 David Haines Anti-inflammatory formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KURIAKOSE NEENA ET AL: "IPL576,092 is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoids.", POSTER, March 2001 (2001-03-01), 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology;New Orleans, Louisiana, USA; March 16-21, 2001, XP002212353, Retrieved from the Internet <URL:http://www.inflazyme.com/scientific_publications/AAAAI576MoA.PDF> [retrieved on 20020902] *
MARSH PETER ET AL: "Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome.", OPHTHALMOLOGY, vol. 106, no. 4, April 1999 (1999-04-01), pages 811 - 816, XP001095766, ISSN: 0161-6420 *
MUNDEN P M ET AL: "MIFEPRISTONE BLOCKS SPECIFIC GLUCOCORTICOID RECEPTOR BINDING IN RABBIT IRIS-CILIARY BODY", ARCHIVES OF OPHTHALMOLOGY, vol. 110, no. 5, 1992, pages 703 - 705, XP001095757, ISSN: 0003-9950 *

Also Published As

Publication number Publication date
EP1392322A1 (en) 2004-03-03
PL367097A1 (en) 2005-02-21
BR0209882A (en) 2004-06-08
US20030008853A1 (en) 2003-01-09
ZA200308770B (en) 2004-11-23
CN1239161C (en) 2006-02-01
CA2447918A1 (en) 2002-11-28
JP2004531560A (en) 2004-10-14
CN1509177A (en) 2004-06-30
MXPA03010633A (en) 2004-03-09

Similar Documents

Publication Publication Date Title
US7026296B2 (en) Methods of treating dry eye disorders
US6872382B1 (en) Use of selective PDE IV inhibitors to treat dry eye disorders
US20050182039A1 (en) Use of Loteprednol etabonate for the treatment of dry eye
US20070110812A1 (en) Ophthalmic composition for dry eye therapy
US20060069075A1 (en) Methods for treating dry eye
EP1744736B1 (en) Method of treating dry eye disorders and uveitis
US6645994B1 (en) Method of treating dry eye disorders
US20030008853A1 (en) Method for treating dry eye disorders
AU2002316133A1 (en) Method of treating dry eye disorders
EP1393277B1 (en) USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS
US7223737B1 (en) Method of treating dry eye disorders using glycosides
US7235556B2 (en) Methods of treating dry eye disorders
AU2002309963A1 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP MX PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002746411

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/08770

Country of ref document: ZA

Ref document number: 200308770

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2447918

Country of ref document: CA

Ref document number: 2002591001

Country of ref document: JP

Ref document number: 028102428

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002316133

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002746411

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002746411

Country of ref document: EP